Showing 2651-2660 of 6036 results for "".
- Allegro Ophthalmics Receives Approval from FDA for Design of Phase 2b/3 Clinical Trial of Risuteganib for the Treatment of Intermediate Dry AMDhttps://modernod.com/news/allegro-ophthalmics-receives-approval-from-fda-for-design-of-phase-2b3-clinical-trial-of-risuteganib-for-the-treatment-of-intermediate-dry-amd/2481527/Allegro Ophthalmics announced that the company has received agreement from the FDA under a Special Protocol Assessment (SPA) for the design of its phase 2b/3 clinical trial of risuteganib (Luminate) for the treatment of intermediate, dry age-related macular degeneration (AMD).
- Kala Receives FDA Fast Track Designation for Human MSC-S Therapy for Persistent Corneal Epithelial Defecthttps://modernod.com/news/kala-pharmaceuticals-receives-fda-fast-track-designation-for-kpi-012-a-human-msc-s-therapy-for-persistent-corneal-epithelial-defect/2481526/The FDA has granted Fast Track designation for Kala Pharmaceuticals' human mesenchymal stem cell secretome (MSC-S) therapy (KPI-012) for the treatment of persistent corneal epithelial defect (PCED). “There is a significant unmet need for patients suffering from PCED, whic
- Peeq Waiva Multipurpose Eyelid Cleansing Device Now Availablehttps://modernod.com/news/peeq-waiva-multipurpose-eyelid-cleansing-device-now-available/2481525/Peeq Pro has announced the launch of the Peeq Waiva, an at-home cleansing device designed for daily use to gently and effectively clean eyelids and the skin around the eyes. When used consistently as part of a patient's at-home eye cleansing routine, the device is designed
- SightGlass Vision Highlights New Myopia Control Spectacle Lens Technologyhttps://modernod.com/news/sightglass-vision-highlights-new-myopia-control-spectacle-lens-technology/2481524/SightGlass Vision will share its myopia control spectacle lens technology at the International Congress of Ophthalmology and Optometry China (COOC), in partnership with Nikon Lenswear. The conference takes place in Shanghai from April 14-16, 2023. Spectacle lenses with SightGlass V
- Radius Announces Software Upgrade for Wearable Device for Perimetric Examinationshttps://modernod.com/news/radius-announces-perimeter-software-upgrade-for-wearable-device/2481518/Radius XR has launched its Radius 1.0 software release for perimetric examinations. Its interface is designed to assist eye care practices in delivering more comprehensive glaucoma management. Radius is a portable Vision Diagnostic and Patient Engagement system that combi
- Aviceda Announces 3 Presentations on AVD-104, its Lead Glyco-mimetic Nanoparticle, As Treatment for GA at ARVOhttps://modernod.com/news/aviceda-announces-3-presentations-on-avd-104-its-lead-glyco-mimetic-nanoparticle-as-treatment-for-ga-at-arvo/2481507/Aviceda Therapeutics announced its upcoming oral and poster presentations at the 2023 Association for Research in Vision and Ophthalmology (ARVO) annual meeting in New Orleans, April 23-27, 2023. Detailed results from each of these three studies will be reported at the conference.
- Pixium Vision Announces FDA Breakthrough Device Designation for the Prima System in Dry AMDhttps://modernod.com/news/pixium-vision-announces-fda-breakthrough-device-designation-for-the-prima-system-in-dry-amd/2481505/The FDA has granted Breakthrough Device Designation to Pixium Vision's Prima System, a photovoltaic substitute of photoreceptors providing simultaneous use of the central prosthetic and peripheral natural vision implanted in human patients with atrophic dry age-related macular
- Cellusion Announces First Patient Transplanted iPSC-Derived Corneal Endothelial Cell Substitute (CLS001)https://modernod.com/news/cellusion-announces-first-patient-transplanted-ipsc-derived-corneal-endothelial-cell-substitute-cls001/2481493/An iPS cell-derived corneal endothelial cell substitute (CLS001) was transplanted to the first patient, according to Cellusion. Research collaborator, Shigeto Shimmura, MD, PhD, Professor of Fujita Health University and Keio University in Japan, provided details of the procedure&nb
- Cognition Therapeutics Announces Development Plans for Oral CT1812 in GA Secondary to Dry AMDhttps://modernod.com/news/cognition-therapeutics-announces-development-plans-for-oral-ct1812-in-ga-secondary-to-dry-amd/2481472/Cognition Therapeutics announced that its investigational new drug (IND) application for CT1812 for geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD) has been cleared by the FDA. Cognition plans to initiate the phase 2 MAGNIFY trial of its oral drug candidate&nb
- Study: Iyuzeh Demonstrated Similar IOP Lowering Efficacy with a Favorable Safety Profile when Compared to Xalatanhttps://modernod.com/news/study-iyuzeh-demonstrated-similar-iop-lowering-efficacy-with-a-favorable-safety-profile-when-compared-to-xalatan-in-glaucoma-patients/2481450/Thea Pharma announced the presentation of phase 3 data on Iyuzeh (latanoprost ophthalmic solution 0.005%) by Jason Bacharach, MD, at the 2023 American Glaucoma Society (AGS) Annual Meeting. The large, pivotal clinical trial demonstrated comparable efficacy of preservative-free